These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 34862246)

  • 21. Monitoring response to neoadjuvant chemotherapy in triple negative breast cancer using circulating tumor DNA.
    Chen JH; Addanki S; Roy D; Bassett R; Kalashnikova E; Spickard E; Kuerer HM; Meas S; Sarli VN; Korkut A; White JB; Rauch GM; Tripathy D; Arun BK; Barcenas CH; Yam C; Sethi H; Rodriguez AA; Liu MC; Moulder SL; Lucci A
    BMC Cancer; 2024 Aug; 24(1):1016. PubMed ID: 39148033
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.
    Magbanua MJM; Brown Swigart L; Ahmed Z; Sayaman RW; Renner D; Kalashnikova E; Hirst GL; Yau C; Wolf DM; Li W; Delson AL; Asare S; Liu MC; Albain K; Chien AJ; Forero-Torres A; Isaacs C; Nanda R; Tripathy D; Rodriguez A; Sethi H; Aleshin A; Rabinowitz M; Perlmutter J; Symmans WF; Yee D; Hylton NM; Esserman LJ; DeMichele AM; Rugo HS; van 't Veer LJ
    Cancer Cell; 2023 Jun; 41(6):1091-1102.e4. PubMed ID: 37146605
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer.
    Yuan Y; Lee JS; Yost SE; Li SM; Frankel PH; Ruel C; Schmolze D; Robinson K; Tang A; Martinez N; Stewart D; Waisman J; Kruper L; Jones V; Menicucci A; Uygun S; Yoder E; van der Baan B; Yim JH; Yeon C; Somlo G; Mortimer J
    Oncologist; 2021 Mar; 26(3):e382-e393. PubMed ID: 33098195
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy.
    Du L; Yau C; Brown-Swigart L; Gould R; Krings G; Hirst GL; Bedrosian I; Layman RM; Carter JM; Klein M; Venters S; Shad S; van der Noordaa M; Chien AJ; Haddad T; Isaacs C; Pusztai L; Albain K; Nanda R; Tripathy D; Liu MC; Boughey J; Schwab R; Hylton N; DeMichele A; Perlmutter J; Yee D; Berry D; Van't Veer L; Valero V; Esserman LJ; Symmans WF
    Ann Oncol; 2021 May; 32(5):642-651. PubMed ID: 33617937
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer.
    McDonald BR; Contente-Cuomo T; Sammut SJ; Odenheimer-Bergman A; Ernst B; Perdigones N; Chin SF; Farooq M; Mejia R; Cronin PA; Anderson KS; Kosiorek HE; Northfelt DW; McCullough AE; Patel BK; Weitzel JN; Slavin TP; Caldas C; Pockaj BA; Murtaza M
    Sci Transl Med; 2019 Aug; 11(504):. PubMed ID: 31391323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial.
    Symmans WF; Yau C; Chen YY; Balassanian R; Klein ME; Pusztai L; Nanda R; Parker BA; Datnow B; Krings G; Wei S; Feldman MD; Duan X; Chen B; Sattar H; Khazai L; Zeck JC; Sams S; Mhawech-Fauceglia P; Rendi M; Sahoo S; Ocal IT; Fan F; LeBeau LG; Vinh T; Troxell ML; Chien AJ; Wallace AM; Forero-Torres A; Ellis E; Albain KS; Murthy RK; Boughey JC; Liu MC; Haley BB; Elias AD; Clark AS; Kemmer K; Isaacs C; Lang JE; Han HS; Edmiston K; Viscusi RK; Northfelt DW; Khan QJ; Leyland-Jones B; Venters SJ; Shad S; Matthews JB; Asare SM; Buxton M; Asare AL; Rugo HS; Schwab RB; Helsten T; Hylton NM; van 't Veer L; Perlmutter J; DeMichele AM; Yee D; Berry DA; Esserman LJ
    JAMA Oncol; 2021 Nov; 7(11):1654-1663. PubMed ID: 34529000
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Value of ultrasound in assessing response to neoadjuvant chemotherapy in breast cancer.
    Lim HF; Sharma A; Gallagher C; Hall P
    Clin Radiol; 2023 Dec; 78(12):912-918. PubMed ID: 37734976
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel.
    Sharma P; López-Tarruella S; García-Saenz JA; Khan QJ; Gómez HL; Prat A; Moreno F; Jerez-Gilarranz Y; Barnadas A; Picornell AC; Monte-Millán MD; González-Rivera M; Massarrah T; Pelaez-Lorenzo B; Palomero MI; González Del Val R; Cortés J; Fuentes-Rivera H; Morales DB; Márquez-Rodas I; Perou CM; Lehn C; Wang YY; Klemp JR; Mammen JV; Wagner JL; Amin AL; O'Dea AP; Heldstab J; Jensen RA; Kimler BF; Godwin AK; Martín M
    Clin Cancer Res; 2018 Dec; 24(23):5820-5829. PubMed ID: 30061361
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Role of Stromal Tumour Infiltrating Lymphocytes (sTIL) Intensity and Programmed Death Ligand 1 () Expression in Breast Cancer Response to Neoadjuvant Therapy in Cipto Mangunkusumo Hospital (CMH), Indonesia.
    Rustamadji P; Felicia D; Wuyung PE; Hellyanti T
    Asian Pac J Cancer Prev; 2023 Oct; 24(10):3459-3465. PubMed ID: 37898851
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early evaluation of circulating tumor DNA as marker of therapeutic efficacy and prognosis in breast cancer patients during primary systemic therapy.
    Wang R; Wang B; Zhang H; Liao X; Shi B; Zhou Y; Zhou C; Yan Y; Zhang W; Wang K; Ge G; Ren Y; Tang X; Gan B; He J; Niu L
    Breast; 2024 Aug; 76():103738. PubMed ID: 38685149
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictive value of PET-CT for pathological response in stages II and III breast cancer patients following neoadjuvant chemotherapy with docetaxel.
    García García-Esquinas MA; Arrazola García J; García-Sáenz JA; Furió-Bacete V; Fuentes Ferrer ME; Ortega Candil A; Cabrera Martín MN; Carreras Delgado JL
    Rev Esp Med Nucl Imagen Mol; 2014; 33(1):14-21. PubMed ID: 23809513
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circulating tumor DNA dynamics using patient-customized assays are associated with outcome in neoadjuvantly treated breast cancer.
    Butler TM; Boniface CT; Johnson-Camacho K; Tabatabaei S; Melendez D; Kelley T; Gray J; Corless CL; Spellman PT
    Cold Spring Harb Mol Case Stud; 2019 Apr; 5(2):. PubMed ID: 30833418
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Axillary Nodal Response to Neoadjuvant T-DM1 Combined with Pertuzumab in a Prospective Phase II Multi-Institution Clinical Trial.
    Weiss A; Jin Q; Waks AG; Yardley D; Spring LM; Wrabel E; Tayob N; Viale G; Krop IE; King TA; Metzger-Filho O
    J Am Coll Surg; 2024 Mar; 238(3):303-311. PubMed ID: 38047578
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Construction of a risk stratification model integrating ctDNA to predict response and survival in neoadjuvant-treated breast cancer.
    Liu Z; Yu B; Su M; Yuan C; Liu C; Wang X; Song X; Li C; Wang F; Ma J; Wu M; Chen D; Yu J; Yu Z
    BMC Med; 2023 Dec; 21(1):493. PubMed ID: 38087296
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis.
    Martín M; Chacón JI; Antón A; Plazaola A; García-Martínez E; Seguí MA; Sánchez-Rovira P; Palacios J; Calvo L; Esteban C; Espinosa E; Barnadas A; Batista N; Guerrero A; Muñoz M; Romio E; Rodríguez-Martín C; Caballero R; Casas MI; Rojo F; Carrasco E; Antolín S
    Oncologist; 2017 Nov; 22(11):1301-1308. PubMed ID: 28701571
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation of Methylated Circulating Tumor DNA With Response to Neoadjuvant Chemotherapy in Breast Cancer Patients.
    Takahashi H; Kagara N; Tanei T; Naoi Y; Shimoda M; Shimomura A; Shimazu K; Kim SJ; Noguchi S
    Clin Breast Cancer; 2017 Feb; 17(1):61-69.e3. PubMed ID: 27395416
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Breast cancer: influence of tumour volume estimation method at MRI on prediction of pathological response to neoadjuvant chemotherapy.
    Henderson SA; Muhammad Gowdh N; Purdie CA; Jordan LB; Evans A; Brunton T; Thompson AM; Vinnicombe S
    Br J Radiol; 2018 Jul; 91(1087):20180123. PubMed ID: 29641224
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast Cancer.
    Miglietta F; Ragazzi M; Fernandes B; Griguolo G; Massa D; Girardi F; Bottosso M; Bisagni A; Zarrilli G; Porra F; Iannaccone D; Dore L; Gaudio M; Santandrea G; Fassan M; Lo Mele M; De Sanctis R; Zambelli A; Bisagni G; Guarneri V; Dieci MV
    Clin Cancer Res; 2023 Sep; 29(17):3429-3437. PubMed ID: 37417941
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modulatory effect of neoadjuvant chemotherapy on biomarkers expression; assessment by digital image analysis and relationship to residual cancer burden in patients with invasive breast cancer.
    Cockburn A; Yan J; Rahardja D; Euhus D; Peng Y; Fang Y; Rumnong Sarode V
    Hum Pathol; 2014 Feb; 45(2):249-58. PubMed ID: 24289969
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Performance of Mid-Treatment Breast Ultrasound and Axillary Ultrasound in Predicting Response to Neoadjuvant Chemotherapy by Breast Cancer Subtype.
    Candelaria RP; Bassett RL; Symmans WF; Ramineni M; Moulder SL; Kuerer HM; Thompson AM; Yang WT
    Oncologist; 2017 Apr; 22(4):394-401. PubMed ID: 28314842
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.